Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now ...

VOV.VN - Vietnam Vaccine JSC (VNVC) began administering the pneumococcal 15-valent conjugate vaccine (PCV15 or Vaxneuvance) ...

Crinetics Pharmaceuticals, Inc.’s CRNX share price has surged by 8.07%, which has investors questioning if this is right time to sell.

The FDA cleared the investigational new drug application of IDE849, a potential first-in-class DLL3-targeted antibody-drug ...

Detailed price information for Bolt Biotherapeutics Inc (BOLT-Q) from The Globe and Mail including charting and trades.

Topline pivotal Phase 3 firmonertinib data. ArriVent anticipates having topline firmonertinib monotherapy data from the event-driven global pivotal FURVENT Phase 3 (NCT05607550) study in 2025 and ...

Researchers developed a biomimetic nanovesicle that crosses the blood-brain barrier, degrades DNA repair proteins, and ...

We recently published a list of 10 Low Risk High Reward Stocks Set to Triple by 2030. In this article, we are going to take a ...

Treatment with an Enhertu regimen significantly improved pathologic complete responses for patients with high-risk ...

In April 2025, our partner Jazz announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of ...

The demand for targeted therapeutics, especially antibody-drug conjugates (ADCs), is fueling growth, alongside advancements in precision medicine. Key drivers include increasing biopharmaceutical R&D ...

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the clearance of an investigational new ...